Given the high expression of PD-L1 in mesothelioma and lung cancer and promising clinical activity of PD-1/PD-L1 checkpoint inhibitors in these cancers, we aimed to evaluate if LMB-100 in combination with αPD-1 antibody will result in greater anti-tumor efficacy. Here, RPL17 is linked to cancer.